Prevention of antimicrobial prescribing among infants following maternal vaccination against respiratory syncytial virus.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 35286196.
- Also identified by DOI 10.1073/pnas.2112410119 and PMC identifier 8944586.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
SignificanceStrategies to reduce consumption of antimicrobial drugs are needed to contain the growing burden of antimicrobial resistance. Respiratory syncytial virus (RSV) is a prominent cause of upper and lower respiratory tract infections, as a single agent and in conjunction with bacterial pathogens, and may thus contribute to the burden of both inappropriately treated viral infections and appropriately treated polymicrobial infections involving bacteria. In a double-blind, randomized, placebo-controlled trial, administering an RSV vaccine to pregnant mothers reduced antimicrobial prescribing among their infants by 12.9% over the first 3 mo of life. Our findings implicate RSV as an important contributor to antimicrobial exposure among infants and demonstrate that this exposure is preventable by use of effective maternal vaccines against RSV.
Medical subject headings
- Anti-Infective Agents
- Respiratory Syncytial Virus Infections
- Respiratory Syncytial Virus Vaccines
- Respiratory Syncytial Virus, Human